Pachychoroid Neovasculopathy (PNV)

Pachychoroid neovasculopathy is an eye condition that happens in the macula, the tiny central area of the retina that gives sharp vision. In PNV, the choroid—the spongy, blood-rich layer under the retina—becomes thick and crowded with large, dilated veins (called “pachyvessels”). Because of this abnormal choroidal circulation, the very thin capillary layer just under the retina (the choriocapillaris) gets stressed and does not feed the retina properly. The retina reacts by growing new, fragile blood vessels under the retinal pigment epithelium (RPE). These new vessels are called type 1 macular neovascularization. They can leak fluid or bleed, blur vision, and distort straight lines. PNV belongs to a family of conditions called the pachychoroid disease spectrum. In this family, a thick choroid and big choroidal veins are the shared features. NaturePMC

PNV is an eye condition where new, abnormal blood vessels grow under the retina (beneath the retinal pigment epithelium—this pattern is called “type 1 macular neovascularization”). It happens in eyes with a pachychoroid, which means the choroid (the blood-rich layer behind the retina) is thicker than usual and contains large, dilated veins (“pachyvessels”). These choroidal changes stress the outer retina and can cause fluid or bleeding, leading to blurred or distorted central vision. PNV sits on the pachychoroid disease spectrum with related conditions like central serous chorioretinopathy (CSC) and polypoidal choroidal vasculopathy (PCV). PNV is not the same as typical age-related macular degeneration (AMD): it often occurs in younger patients, lacks drusen, and shows thick choroid/pachyvessels on scans. EyeWikiPubMedNature

PNV is different from age-related macular degeneration (AMD). In AMD, soft drusen (fatty deposits) are common and the disease is tightly tied to age-related changes. In PNV, drusen are usually absent, and the problem is more about choroidal congestion and thickening beneath the macula. The abnormal vessels also live under the RPE (type 1), often creating a subtle, shallow, irregular “bump” of the RPE on scans. Recognizing this difference matters because it helps doctors choose the right tests and treatments. EyeWikiRetina Today

Why does PNV happen?

Think of the choroid as a dense, flexible sponge filled with many blood vessels that supplies oxygen and nutrients to the outer retina. In pachychoroid eyes, some of the large choroidal veins are dilated and there is venous congestion. This congestion raises local pressure, squeezes the overlying fine capillary layer, and thins the supportive tissue above it. Over time this stress injures the RPE and outer retina. The eye then tries to compensate by growing new blood vessels under the RPE (type 1 neovascularization). These vessels are fragile, and they tend to leak or bleed, which blurs central vision and bends straight lines. In some eyes, the network of new vessels can later form aneurysmal “polyp”-like outpouchings, which marks conversion to aneurysmal type 1 neovascularization (also called polypoidal choroidal vasculopathy, PCV)—a related but distinct endpoint on the same spectrum. Nature+1PMC

Types of PNV

1) Typical macular PNV (subfoveal or parafoveal).
This is the common pattern. The abnormal new vessels grow beneath the RPE in or near the very center of vision. The choroid is thick and has large veins right under the lesion. On scans, doctors often see a shallow, irregular pigment epithelial detachment (shallow irregular PED) with a “double-layer sign.” Retina Today

2) PNV with shallow irregular PED dominance.
In this pattern, the main clue is that the RPE looks slightly lifted and uneven over a wide area on OCT. The space under the RPE is laced with a flat neovascular network. The choroid under it shows pachyvessels and overall thickening. Retina Today

3) Quiescent (non-leaking) PNV detectable on OCT angiography.
Sometimes, a new vessel network exists under the RPE without obvious fluid or leakage. Dye angiography can miss it, but OCT angiography (OCTA) can pick it up. People may have few symptoms at this stage, and careful monitoring is important. ScienceDirect

4) PNV with conversion to aneurysmal type 1 neovascularization (PCV).
In a subset of eyes, the flat network later develops bulb-like aneurysmal dilations (“polyps”), shifting the diagnosis toward PCV. This change matters because it can alter treatment choice and response. ophthalmologyretina.orgPMC

5) Peripapillary pachychoroid neovasculopathy.
In this less common type, the new vessels arise near the optic disc rather than the fovea. The choroid is still thick and venous congestion features are still present, but symptoms and exam focus around the peripapillary region. PMC

6) PNV on a background of chronic central serous chorioretinopathy (CSC).
Some eyes have had recurrent or chronic CSC and later develop a type 1 neovascular network under the RPE—essentially evolving from fluid-prone CSC into PNV. This link is common enough that doctors routinely check for PNV when chronic CSC is not settling as expected. PMC

In everyday language: no matter the subtype, the shared theme is a thick, congested choroid with big veins that pushes the system toward sub-RPE new vessel growth. Nature

Causes and risk factors

Note: In PNV, “cause” usually means a risk factor or driver that pushes the choroid toward congestion and the retina toward new vessel growth. Not every person has every factor.

1. Pachychoroid anatomy. Some people naturally have a thicker-than-average choroid with large, dilated veins (pachyvessels). This sets the stage for congestion and later neovascular growth. PMC

2. Choroidal venous congestion. When the choroidal outflow is bottlenecked, pressure builds, the capillaries suffer, and the RPE gets stressed. Over time, this stress can invite new vessel growth under the RPE. Nature

3. History of central serous chorioretinopathy (CSC). Repeated or long-lasting CSC can damage the RPE and make the retina prone to type 1 neovascularization, which is essentially PNV. PMC

4. Older adult age. PNV is more often found in middle-aged and older adults, likely because choroidal veins and the RPE accumulate stress and micro-injury with time. (General epidemiology statement derived from reviews.) PMC

5. Male sex for some pachychoroid phenotypes. Several pachychoroid disorders, especially CSC, skew male; this tendency can increase the pool of people at risk of evolving into PNV. (Context from pachychoroid spectrum reviews.) PMC

6. Genetic susceptibility distinct from AMD. PNV tends to lack AMD-style drusen and seems to follow different genetic patterns than typical AMD, suggesting a separate pathway that begins in the choroid rather than the RPE itself. EyeWiki

7. Stress-hormone influence (cortisol). Conditions or medicines that raise corticosteroid levels can worsen choroidal leakage and RPE stress in the pachychoroid spectrum, nudging some eyes toward neovascular change. (Supportive in CSC literature within the spectrum.) PMC

8. Exogenous steroid exposure. Oral, inhaled, topical, or injected steroids can aggravate pachychoroid physiology in susceptible people, sometimes preceding PNV evolution after chronic effects. (Extrapolated from pachychoroid/CSC literature.) PMC

9. Hypertension and vascular strain. High blood pressure can load the choroidal circulation and increase venous pressure, compounding congestion in thick choroids.

10. Sleep apnea. Repeated nighttime oxygen dips and pressure fluctuations may stress choroidal vessels and inflate venous congestion, a pattern linked with CSC and plausibly relevant to PNV evolution. (Spectrum context.) PMC

11. Sympathetic overdrive. People with high sympathetic tone (fast “fight-or-flight” baseline) may have vascular reactivity that worsens choroidal leakage.

12. Smoking. Smoking damages blood vessels and may stiffen the vascular bed, making venous congestion worse.

13. Metabolic syndrome features. Obesity, insulin resistance, and abnormal lipids strain microvessels and can compound choroidal dysfunction.

14. Caffeine and stimulants in excess. Strong vasomotor agents can alter choroidal blood flow, occasionally tipping balance in vulnerable eyes.

15. Choroidal thickness that varies with posture or time. Some pachychoroid eyes show day-night or positional thickness swings, which can repeatedly stress the RPE.

16. Scleral factors that impede outflow. A relatively stiff or thick sclera might impair venous egress, allowing venous pressure to build in the choroid.

17. Local inflammation around the RPE-choriocapillaris interface. Even low-grade, chronic inflammation can thin the choriocapillaris over pachyvessels and foster neovascular growth.

18. Sunlight and oxidative stress over decades. Lifelong light exposure increases oxidative load on the RPE and outer retina, which are already stressed by choroidal congestion.

19. Refractive and anatomic factors. Eyes that are slightly hyperopic (shorter) may have thicker choroids, contributing to the pachychoroid milieu.

20. Family clustering of pachychoroid traits. Pachychoroid signs sometimes run in families, increasing the background risk of PNV in relatives. (Spectrum narrative.) PMC

Takeaway: PNV does not need drusen to form. It usually starts with a thick, congested choroid, places pressure on the fine capillary layer, injures the RPE, and then grows sub-RPE vessels that leak or bleed. Nature

Symptoms

1. Blurred central vision. The center of the visual field looks foggy or smeared, especially when reading fine print.

2. Metamorphopsia (bent lines). Straight lines (like door frames or grid lines) look wavy or kinked, because fluid or a shallow RPE bump distorts the macular layers.

3. Micropsia or magnification changes. Letters can look smaller or uneven, reflecting subtle stretching of the photoreceptors over fluid pockets.

4. Gray or dark patch near the center. A soft central spot or “missing patch” can appear if fluid or sub-RPE change blocks normal photoreceptor function.

5. Difficulty reading. Words swim, blur, or skip, and frequent re-reading becomes necessary.

6. Fluctuating vision from day to day. Vision may be better one day and worse the next, mirroring changes in subretinal fluid volume.

7. Slow recovery after bright light. After looking at bright light, the center may take longer to clear, reflecting outer retinal stress.

8. Color fading. Colors may look washed-out or less rich in the affected eye.

9. Poor contrast. Faces or letters on gray backgrounds may be hard to tell apart, especially in low light.

10. Trouble in dim light. Tasks at dusk or in restaurants feel harder, due to impaired outer retinal support.

11. Central shimmering or flicker. Some people notice a subtle shimmer over the reading area.

12. Occasional mild central ache or eye strain. Reading for long periods becomes uncomfortable because the visual system is working to overcome distortion.

13. Double or shadow images in one eye. A ghost image can appear due to macular contour irregularity.

14. Need for stronger reading light. People turn up lights or use brighter lamps to compensate for reduced macular efficiency.

15. Reduced depth or fine detail perception. Threading a needle or seeing tiny textures becomes more difficult.

Diagnostic tests

Important note: PNV is a multimodal imaging diagnosis. Doctors confirm it by putting together clinical exam findings with OCT, OCT-angiography, and dye angiography. Imaging shows the thick choroid, pachyvessels, shallow irregular PED, and the sub-RPE neovascular network. PMC

A) Physical exam–based tests

1) Best-corrected visual acuity (distance and near).
You read letters on a chart to measure clarity. In PNV, acuity may drop if the macula has fluid or if the RPE/photoreceptors are stressed. Tracking acuity over time helps judge treatment needs.

2) Pupil assessment and light reflexes.
Doctors check pupils to ensure the optic nerve and retinal signaling are intact. PNV usually does not cause a strong afferent defect, but this exam is routine to rule out other problems.

3) Intraocular pressure measurement.
Pressure is measured to look for glaucoma risk or treatment constraints. While not specific to PNV, it is standard and important before certain medications or procedures.

4) Slit-lamp biomicroscopy of the macula with a high-power lens.
After dilation, the doctor inspects the macula directly. They may see subtle RPE changes, tiny hemorrhages, or serous detachments suggesting activity. This exam guides which imaging to do next.

5) Confrontation visual fields.
A quick check looks for central or paracentral field defects. In PNV, small central defects can correlate with structural changes.

B) Manual/perceptual tests

6) Amsler grid.
You stare at a dot in the center of a small square grid. Wavy lines or missing boxes suggest macular distortion from fluid or a shallow irregular PED.

7) Pinhole acuity.
A simple pinhole can bypass refractive blur. If pinhole helps, part of the blur is optical; if not, macular disease is a stronger contributor.

8) Photostress recovery test.
After a bright light, time how long it takes to read again. A delayed recovery hints at outer retinal/RPE stress, which is common in PNV.

9) Near reading speed (Jaeger cards or standardized reading charts).
Slower reading speed, frequent skipping, or fatigue quantify functional impact of distortion and blur.

10) Contrast sensitivity (e.g., Pelli-Robson).
This measures how well you see faint differences between shades. PNV often reduces contrast sensitivity even when letter acuity looks fairly good.

C) Laboratory and pathological tests

Labs are not used to diagnose PNV directly. They help identify contributors (like steroid exposure or metabolic strain) and optimize treatment safety.

11) Cortisol assessment (morning serum or 24-h urine free cortisol).
If history suggests endogenous hypercortisolism or heavy steroid exposure, testing can confirm a systemic driver that worsens pachychoroid physiology. PMC

12) Glycemic assessment (fasting glucose or HbA1c).
High blood sugar stiffens and stresses microvessels. Knowing the baseline helps address vascular risk during care.

13) Lipid profile.
Abnormal lipids add vascular strain. Results support broader risk management and may affect long-term outcomes.

D) Electrodiagnostic tests

14) Multifocal electroretinography (mfERG).
mfERG maps the local function of the macula. In PNV, it can show reduced responses where fluid or RPE damage is present, documenting how the disease affects retinal cells.

15) Visual evoked potential (VEP).
VEP checks the signal from the retina to the brain. While less specific for PNV, it helps exclude optic-nerve-level issues when symptoms are atypical.

E) Imaging tests (the cornerstone)

16) Spectral-domain or swept-source OCT with enhanced depth imaging (EDI).
OCT is the key, non-invasive scan. It creates microscopic cross-sections of the retina and choroid. In PNV, OCT often shows a shallow, irregular RPE detachment, subretinal or sub-RPE fluid, and a thickened choroid with large “pachyvessels” beneath. EDI or swept-source settings let doctors see the choroid clearly and measure thickness. PMC+1

17) OCT angiography (OCTA).
OCTA maps blood flow without dye. It can directly visualize the flat, sub-RPE neovascular network in PNV, even when dye tests look subtle, and it’s particularly helpful for quiescent networks. ScienceDirect

18) Fundus fluorescein angiography (FA).
FA uses an intravenous dye to highlight leakage patterns from the retina and RPE. In PNV, FA can show late leakage or pooling, but the flat, sub-RPE network may be less obvious than on OCTA. FA also helps rule out classic AMD patterns.

19) Indocyanine green angiography (ICGA).
ICGA is excellent for choroidal circulation. It can outline pachyvessels, areas of choroidal hyperpermeability, and, if present, aneurysmal polyp-like lesions that indicate conversion toward PCV. PMC+1

20) Fundus autofluorescence (FAF) and color fundus photography (including widefield).
FAF shows RPE health by mapping lipofuscin signals; it can reveal stress and damage patterns from longstanding leakage. Color photos document tiny hemorrhages, exudates, and pigment changes and help track response over time.

Non-pharmacological treatments

These measures support the retina and choroid, reduce triggers, and complement in-office treatments. For each item you’ll see: description → purpose → simple mechanism.

1. Education & early action. Learn PNV warning signs (new distortion, central blur, gray spots). Purpose: faster care. Mechanism: you seek help before fluid/bleed harms the macula.

2. Amsler grid home monitoring. Check a small grid card daily with reading glasses. Purpose: catch new distortion quickly. Mechanism: detects macular changes at home.

3. Scheduled follow-ups with retina imaging. Keep OCT/OCTA visits even when you feel fine. Purpose: track fluid or scar early. Mechanism: objective scans spot relapse before vision drops.

4. Stress management (CBT, mindfulness, breathing). Purpose: reduce CSC-type triggers that can worsen pachychoroid activity. Mechanism: lowers sympathetic drive and cortisol surges that may affect choroidal circulation.

5. Sleep optimization. Regular schedule; screen curfew; dark, cool room; treat insomnia. Purpose: stabilize hormonal and autonomic tone. Mechanism: better sleep dampens stress pathways linked to choroidal congestion.

6. Screening for sleep apnea (OSA). If you snore or feel unrefreshed, get evaluated. Purpose: OSA is associated with vascular dysregulation that can aggravate pachychoroid features. Mechanism: CPAP lowers nocturnal hypoxia and venous pressure swings.

7. Stop unnecessary corticosteroids. Review inhalers, creams, pills with your prescribers. Purpose: steroids can worsen CSC-like activity. Mechanism: mineralocorticoid/glucocorticoid effects can increase choroidal leakage.

8. Blood pressure control. Aim for doctor-advised targets. Purpose: protect fragile new vessels and the choroid. Mechanism: steadier perfusion reduces leak/bleed risk.

9. Smoking cessation. Purpose: improve choroidal and retinal oxygen delivery. Mechanism: fewer vasoconstrictors and oxidative toxins reaching the macula.

10. Limit high stimulants (excess caffeine/energy drinks). Purpose: avoid sympathetic surges. Mechanism: reduces choroidal venous congestion peaks.

11. Hydration & moderate salt. Purpose: keep stable blood volume without spikes. Mechanism: smooths venous pressure shifts in the choroid.

12. Treat reflux/anxiety that worsens sleep. Purpose: help overall autonomic balance. Mechanism: less night-time arousal → steadier choroidal flow.

13. Ergonomics & regular breaks for near work. Purpose: reduce eye strain so subtle vision changes are noticed. Mechanism: frequent pauses make monitoring easier.

14. Blue-light and glare control when symptomatic. Use matte screens, antireflection lenses. Purpose: comfort in the presence of macular fluid. Mechanism: reduces photostress.

15. UV protection outdoors. Purpose: protect RPE and macula. Mechanism: sunglasses reduce cumulative light-induced stress.

16. Heart-healthy, eye-friendly diet pattern. Leafy greens, fish, nuts, colorful produce. Purpose: support retinal metabolism. Mechanism: antioxidants and omega-3s help photoreceptors and RPE.

17. Moderate physical activity. Purpose: vascular health. Mechanism: improves endothelial function and blood pressure.

18. Avoid heavy Valsalva spikes (straining, sudden heavy lifting). Purpose: reduce choroidal venous pressure bursts. Mechanism: fewer abrupt pressure surges to fragile vessels.

19. Medication review for vasoconstrictors/decongestants. Purpose: avoid agents that could raise sympathetic tone. Mechanism: keeps choroidal flow steadier (only change meds with your doctor).

20. Observation (in selected stable cases). Purpose: sometimes the best step is watchful waiting with imaging if vision is good and the neovascularization is quiescent. Mechanism: avoids overtreatment while staying safe with close OCT/OCTA follow-up. NaturePMC

---

Drug treatments

Important: Drug choices and dosing are individualized by a retina specialist. Anti-VEGF injections are the mainstay; photodynamic therapy (PDT) with verteporfin is often added in PNV. Some items below are “off-label” for PNV (used based on studies and expert practice patterns). I include typical nAMD-style dosing schedules as a practical anchor; your doctor may modify this.

1. Aflibercept (anti-VEGF “trap”).
   Class: Anti-VEGF biologic. Dose/Timing: 2 mg intravitreal; often 3 monthly loading injections, then “treat-and-extend” (intervals gradually stretched if dry). Purpose: dry up fluid, stabilize or improve vision. Mechanism: binds VEGF-A/VEGF-B/PlGF to stop new vessel leak and growth. Common side effects: eye irritation, transient floaters; rare serious risks: infection, inflammation, retinal tear/detachment. Evidence in PNV: effective; some series show good anatomical control and sometimes fewer injections compared with typical nAMD. Nature+1PMC

2. Ranibizumab (anti-VEGF-A Fab).
   Class: Anti-VEGF. Dose/Timing: 0.5 mg intravitreal; similar loading then PRN/extend. Purpose/Mechanism: blocks VEGF-A to shut down leakage. Side effects: as above. Evidence: works in PNV; outcomes broadly comparable to aflibercept in several cohorts. Nature+1

3. Bevacizumab (anti-VEGF-A; off-label intraocular).
   Class: Anti-VEGF. Dose/Timing: 1.25 mg intravitreal; monthly then extend if dry. Purpose/Mechanism: same anti-VEGF effect; cost-effective option. Side effects: similar class effects. Evidence: commonly used; effectiveness shown in pachychoroid cohorts, though some data suggest aflibercept may dry better in certain PNV eyes. PMC

4. Faricimab (bispecific anti-VEGF-A/anti-Ang-2).
   Class: Dual-pathway biologic. Dose/Timing: 6 mg intravitreal; loading then extend (off-label in PNV; labeled for nAMD/DME). Purpose: reduce leakage and possibly allow longer intervals. Mechanism: blocks VEGF-A and Ang-2 to stabilize vessels. Side effects: similar injection risks; report any pain, redness, or vision drop immediately. Evidence: growing real-world use; limited PNV-specific data—consider in specialist hands. PMC

5. Brolucizumab (anti-VEGF single-chain antibody).
   Class: Anti-VEGF. Dose/Timing: 6 mg intravitreal; loading then extend (caution). Purpose: potent drying; longer intervals in some patients. Mechanism: blocks VEGF-A. Side effects: higher risk of intraocular inflammation/vasculitis than other agents—requires careful selection and counseling.

6. Conbercept (anti-VEGF; region-specific).
   Class: Anti-VEGF fusion protein (available in some countries). Dose/Timing: typical anti-VEGF schedules (specialist discretion). Purpose/Mechanism/Side effects: class-consistent; used where available for PNV.

7. Verteporfin (PDT drug; given by IV before laser activation).
   Class: Photosensitizer used in photodynamic therapy. Dose/Timing: typically 6 mg/m² IV over 10 min, then a low-fluence or reduced-dose laser is applied to activate the drug at the lesion. Purpose: close down the abnormal choroidal neovessels while sparing surrounding tissue; particularly useful in PNV, often combined with anti-VEGF. Side effects: transient back pain during infusion, photosensitivity for ~48 h (strict sun avoidance), rare visual decrease. Evidence: PDT + anti-VEGF is effective for PNV, especially without polypoidal lesions, and can reduce retreatment burden. PLOSPMCNature

8. Switch strategy (e.g., from bevacizumab/ranibizumab to aflibercept).
   Class: Treatment approach rather than a new drug. Dose/Timing: as per target agent. Purpose: achieve better drying when response is incomplete. Mechanism: different binding profiles may better neutralize VEGF in PNV. Evidence: switching to aflibercept improved anatomy in non-responders in several series. Nature

9. Mineralocorticoid receptor antagonists (eplerenone/spironolactone) — selective use.
   Class: Oral MR antagonists. Dose/Timing: eplerenone 25–50 mg daily (monitor potassium/renal function). Purpose: sometimes considered when a CSC component drives activity; not core therapy for PNV. Mechanism: reduces choroidal leakage in CSC physiology. Side effects: hyperkalemia, dizziness, low blood pressure; avoid without physician oversight. (Evidence in PNV is limited; discuss risks/benefits with your retina/medical team.)

10. Acetazolamide (selected cases with CSC features).
    Class: Carbonic anhydrase inhibitor (oral). Dose/Timing: e.g., 250 mg 1–2×/day short courses (renal checks required). Purpose: promote fluid resorption in CSC-like states; not standard for PNV. Mechanism: alters fluid movement across RPE. Side effects: tingling, taste changes, kidney stone risk. (Use only if your specialist recommends.)

---

Dietary molecular supplements

Supplements do not replace injections or PDT. Use them as supportive care after discussing interactions with your doctor.

1. Lutein 10 mg/day. Function: macular pigment support. Mechanism: filters blue light; antioxidant at photoreceptors.

2. Zeaxanthin 2 mg/day. Function/Mechanism: pairs with lutein to protect the fovea; antioxidant shield.

3. Omega-3s (EPA+DHA ≈ 1–2 g/day combined). Function: vascular and retinal membrane health. Mechanism: anti-inflammatory lipid mediators; may stabilize microvasculature.

4. Vitamin C 500 mg/day. Function: antioxidant recycling (vitamin E). Mechanism: quenches oxidative stress in RPE/retina.

5. Vitamin E 200–400 IU/day. Function: lipid-phase antioxidant. Mechanism: helps protect photoreceptor membranes.

6. Zinc 25–40 mg elemental/day + Copper 2 mg/day. Function: RPE enzyme cofactor. Mechanism: supports antioxidant enzymes; copper prevents deficiency from zinc.

7. Astaxanthin 6–12 mg/day. Function: potent xanthophyll antioxidant. Mechanism: crosses retinal tissues; reduces oxidative stress.

8. Resveratrol 150–250 mg/day. Function: endothelial support. Mechanism: modulates oxidative and angiogenic signaling.

9. Curcumin 500–1,000 mg/day with piperine (if tolerated). Function: anti-inflammatory adjunct. Mechanism: NF-κB/VEGF pathway modulation in lab models.

10. Bilberry (standardized anthocyanins 80–160 mg/day). Function: microvascular support and visual comfort. Mechanism: antioxidant/vasoactive flavonoids.

---

Regenerative / stem-cell / immune-booster

There are no approved stem-cell, “hard immunity booster,” or regenerative drugs for PNV at this time. Using unproven products can be dangerous. Here’s what’s being researched (concept level only—no approved dosing for PNV):

1. iPSC-derived retinal pigment epithelium (RPE) cell therapy.
   Function: replace damaged RPE. Mechanism: cell transplantation to support photoreceptors. (Investigational in AMD; not established for PNV.)

2. RPE patch/monolayer implants.
   Function: structural support to diseased macula. Mechanism: bioengineered RPE sheets. (Experimental.)

3. Gene therapy to reduce intraocular VEGF (e.g., anti-VEGF gene delivery).
   Function: long-term VEGF suppression. Mechanism: viral vector drives anti-VEGF production in the eye. (Trials mainly in nAMD.)

4. Long-acting biologic delivery systems.
   Function: extend anti-VEGF effect. Mechanism: sustained release in the eye. (Mixed real-world experience; not regenerative.)

5. Angiopoietin-Tie2 pathway modulation (e.g., faricimab concept).
   Function: stabilize leaky vessels. Mechanism: dual VEGF/Ang-2 blockade. (Agent approved for other retinal diseases; PNV use is specialist-directed.)

6. Complement-pathway inhibitors.
   Function: target inflammatory cascades. Mechanism: dampen complement activity. (Approved for geographic atrophy in AMD, not PNV.)

If you’re curious about a trial, ask your retina specialist to check eligibility on recognized registries. ClinicalTrials.gov

---

Procedures / “surgeries

1. Photodynamic therapy (PDT) with verteporfin.
   What: IV drug + targeted low-fluence laser to the lesion.
   Why: selectively shuts down abnormal sub-RPE vessels and reduces choroidal hyperpermeability; often paired with anti-VEGF to enhance durability. PLOSPMC

2. Anti-VEGF intravitreal injections.
   What: tiny injection into the vitreous under sterile conditions.
   Why: first-line to dry fluid, prevent bleeding, and preserve vision in PNV. Nature

3. Combined PDT + anti-VEGF same-day or staged.
   What: both treatments in a planned sequence.
   Why: common PNV strategy—can improve outcomes and reduce retreatment in selected patients. Nature

4. Subthreshold (micropulse) laser (selected extrafoveal/persistent CSC-like sites).
   What: low-energy, non-damaging laser to RPE.
   Why: modulate RPE pump where CSC-type leakage persists outside the fovea; not a primary PNV fix, but sometimes used as an adjunct.

5. Vitrectomy with subretinal tPA for dense submacular hemorrhage (rare, severe cases).
   What: surgical clearing of large, vision-threatening bleeds.
   Why: to move/disperse clot away from the fovea when hemorrhage is massive and acute.

---

Prevention tips

1. Keep regular retina check-ups and home Amsler grid tests.

2. Stop smoking; avoid secondhand smoke.

3. Review and limit steroid use with your doctors.

4. Treat sleep apnea and improve sleep quality.

5. Manage blood pressure, lipids, and diabetes as advised.

6. Reduce chronic stress with daily brief relaxation practice.

7. Limit excessive caffeine/energy drinks.

8. Stay hydrated and avoid large salt surges.

9. Exercise moderately most days of the week.

10. Wear UV-blocking sunglasses in bright sunlight.

---

When to see a doctor

• New or worsening distortion (straight lines look wavy), central blur, or a gray/black spot in central vision.

• Sudden drop in vision or new central scotoma.

• Fresh floaters/flashes or a curtain over vision (could indicate detachment—emergency).

• Pain, redness, or vision loss after an injection (possible infection—urgent).

• Any new bleed within the eye or sudden worsening on Amsler.

---

What to eat and what to avoid

1. Eat: dark leafy greens (spinach, kale) several times weekly—macular pigments support.

2. Eat: oily fish (salmon, sardines, mackerel) 2×/week—omega-3s for membranes.

3. Eat: colorful fruit/veg (berries, citrus, bell peppers)—broad antioxidants.

4. Eat: nuts and seeds (walnuts, almonds, flax/chia)—healthy fats and micronutrients.

5. Eat: eggs (yolk has lutein/zeaxanthin) if allowed by your dietician.

6. Avoid/limit: heavy smoking and alcohol—vascular and oxidative stressors.

7. Avoid/limit: ultra-processed, high-salt foods—pressure and fluid spikes.

8. Avoid/limit: sugary, high-glycemic snacks—glucose swings harm vessels.

9. Avoid/limit: excess caffeine/energy drinks—sympathetic surges.

10. Avoid: megadose supplements without guidance—some can interact with heart/kidney meds.

---

Frequently asked questions

1) Is PNV the same as wet AMD?
No. Both have new leaky vessels, but PNV usually occurs in eyes with a thick choroid and pachyvessels, often without drusen and sometimes at a younger age. This matters because PDT is used more often in PNV along with anti-VEGF. EyeWikiNature

2) Can PNV get better?
Yes. With anti-VEGF injections and (when needed) PDT, many patients reduce fluid and stabilize or improve vision. Early treatment works best. NaturePLOS

3) Will I need injections forever?
Not always. Some PNV eyes need fewer injections than typical AMD, especially if PDT is added, but plans are individualized. PMC

4) Why do doctors sometimes add PDT?
Because PNV involves choroidal congestion and sub-RPE neovascular tissue; PDT targets that bed and can make results more durable with fewer retreatments in selected cases. PLOS

5) Can glasses or eye drops fix PNV?
No. Glasses don’t treat leakage or bleeding. Most drops don’t reach sub-RPE vessels. Injections and/or PDT are the effective treatments.

6) Are supplements required?
No. They’re optional adjuncts. A balanced, heart-healthy diet is more important. Supplements can help overall retinal support but do not replace medical treatments.

7) Is there a cure?
PNV is manageable rather than “curable.” Many people maintain good vision long-term with the right plan and follow-up.

8) Can stress or poor sleep really affect it?
They can exacerbate pachychoroid/CSC-type physiology in some people, so stress and sleep management are worthwhile.

9) Is PNV hereditary?
There’s no simple inheritance pattern. Family traits like choroidal thickness or vascular responses may play roles; research is ongoing.

10) What if injections stop working?
Your doctor may switch anti-VEGF agents or add PDT. Imaging guides the choice. Nature

11) Is PNV rare?
It’s under-recognized and can be misdiagnosed as AMD. In some clinics, a significant portion of “wet AMD” cases actually meet PNV features. BioMed Central

12) Can I fly or exercise after treatment?
Yes, usually after the first 24–48 hours, unless your doctor advises otherwise. Avoid contact sports right after an injection.

13) What side effects should I watch for after injections?
Urgent signs: increasing pain, redness, pus-like discharge, or big vision drop. Mild scratchiness/floaters are common and usually settle.

14) Will both eyes be affected?
Either eye can be affected; the fellow eye needs periodic checks. Your doctor will tailor monitoring.

15) How often should I be seen?
Often monthly during the active phase, then treat-and-extend to longer intervals if the macula stays dry. Your plan depends on imaging and vision.

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: August 19, 2025.